Generic and Non-Prescription Drugs M&A update, 14–28 September 2026
A bi-weekly update on the Generic and Non-Prescription Drugs sector for September 14–28, 2026, covering share-price moves across ten covered names, the period's approval and launch news, and the standing M&A precedent record — built for operators, acquirers and advisers tracking the space.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Generic and Non-Prescription Drugs Sector Outlook — September 2026
Key figures
- Sector median move
- +8.8%
- close-to-close vs S&P 500 +0.8%
- AMRX price move
- +19.0%
- period leader
- Precedent deal multiple
- 11.7x
- median EV/LTM EBITDA, 40 recorded deals
- Premium tier multiple
- 12.3x
- vs 7.5x sector median
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS
Executive summary
Across September 14–28, 2026, eight of ten covered generic and non-prescription drug names rose, with a median move of +8.8% against the S&P 500's +0.8%. Amneal Pharmaceuticals led at +19.0%, tracking its FDA approval and launch of lanreotide injection, while Viatris' Japanese approval of WAKIX also stood out. No new transactions arrived in the window, leaving the precedent record at a median of 11.7x EV/EBITDA against a 7.5x sector median. The period's evidence points to launch execution, not deal-making, as the driver of value in this window.
Key findings
- 8 of 10 covered names rose; median move was +8.8%, ahead of the S&P 500 at +0.8%
- Amneal led at +19.0% on FDA approval and launch of lanreotide injection
- No new transactions arrived; precedent record holds at 11.7x EV/EBITDA
- Premium-tier names carry 12.3x EV/EBITDA vs 7.5x sector median
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS
This is the cover page for the Generic and Non-Prescription Drugs bi-weekly industry events and M&A update covering September 14–28, 2026.
This bi-weekly update covers what changed, who moved, what transacted and what it means for the generic and non-prescription drugs sector over September 14–28, 2026. We'll walk through the market moves, the news behind them, and the transaction record so you leave with a clear read of the period.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS Launch Execution Earns the Premium While Buyers Stay Quiet This update covers sector news, share-price moves and transaction activity for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Approvals and Launch News, Not Transactions, Set the Direction of the Set
This page summarizes the two-week period's public market moves, drivers and transaction record in one view.
Approvals and launch news, not transactions, set the direction of the set this period. Eight of ten covered names rose, with a median move of +8.8% against the S&P 500's +0.8%, and Amneal led the group at +19.0%. No new transactions arrived to reprice the reference set, so the trailing record — a median of 11.7x EV/EBITDA — still anchors valuation conversations. That combination tells us where the market is already paying for capability, and where the deal record has yet to catch up.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Approvals and Launch News, Not Transactions, Set the Direction of the Set The two-week period in one page · 10 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 8 of 10 Covered Names Rose; The Median Move Was +8.8% The median move of +8.8% ran ahead of the S&P 500 at +0.8%. Amneal Pharmaceuticals, Inc. (AMRX) led at +19.0% and Amphastar Pharmaceuticals, Inc. (AMPH) followed at +14.6%, while Prestige Consumer Healthcare Inc. (PBH) was the softest at -1.4%. 2 Complex Injectables and New Approvals Carried the Period's News Flow Amneal announced FDA approval and immediate launch of lanreotide injection with in-house production behind it, and Viatris Inc. (VTRS) announced Japanese approval of WAKIX. NeuraCap read: launch cadence in hard-to-replicate dosage forms was the period's dominant theme. 3 The Premium Sat with the Names Adding Dosage-Form Capability AMRX, a Premium-tier name in NeuraCap's standing view, posted the largest gain of the window at +19.0%. The Premium tier carries a median of 12.3x EV/EBITDA against a sector median of 7.5x, and the period's news flow was consistent with that ordering rather than a challenge to it. 4 No New Transactions Arrived to Reprice the Reference Set No material sector transactions were announced during the period. The trailing transaction record still carries a median of 11.7x EV/EBITDA, above the 7.5x sector median on CY2027E EBITDA. +19.0% Best mover — AMRX worst: PBH -1.4% · 8 up / 2 down of 10 covered +8.8% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
Approvals and Launches Did the Work at the Top of the Set
This page ranks the ten covered names by share-price move for the period and flags the materiality bar.
Amneal Pharmaceuticals led the covered set at +19.0%, with Amphastar Pharmaceuticals following at +14.6%, while Prestige Consumer Healthcare was the softest performer at -1.4%. The sector median move of +8.8% cleared the period's materiality bar for several names but not all, so the dispersion itself is informative. We attribute each move only to filings and headlines recorded in the window, and where no driver is recorded the page says so plainly. That discipline is what lets you trust the read on any single name.
Everything on this page
PUBLIC MARKET MOVERS Approvals and Launches Did the Work at the Top of the Set Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +8.8% · S&P 500 +0.8% · materiality bar ±13.3% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +8.8% Amneal Pharmaceuticals, Inc. (AMRX) +19.0% Shares moved following Amneal's announced FDA approval and immediate launch of lanreotide injection, which adds a long-acting oncology treatment to its complex injectables portfolio with in-house production behind supply. A launch in a dosage form few filers can replicate still moves a Premium-tier name more than base business volume. COMPANY-SPECIFIC Amphastar Pharmaceuticals, Inc. (AMPH) +14.6% No notable in-window news was identified that clearly explains the move. At +14.6%, Amphastar ran ahead of the +8.8% median for the covered set. Core-tier names can travel with the set's direction even when the period's record offers no single driver. UNEXPLAINED Prestige Consumer Healthcare Inc. (PBH) -1.4% No notable in-window news was identified that clearly explains the move. At -1.4%, Prestige Consumer Healthcare sat below the +8.8% median for the covered set. Consumer self-care brands moved on their own clock while prescription launch news set the pace. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
What Companies Actually Did: Approvals, Launches and Clinical Evidence
This page lists the period's highest-impact company announcements, each linked to its underlying filing or article.
Amneal announced FDA approval and immediate launch of lanreotide injection, produced in-house, and Viatris announced Japanese approval of WAKIX — both sit behind the period's strongest share-price moves. We read these as evidence that launch cadence in harder-to-replicate dosage forms is the theme driving the market's attention right now. Every event on this page links to its source, so the underlying filing or article can be checked directly. That traceability is what turns a headline into a decision input.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Approvals, Launches and Clinical Evidence The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 21 · NEWS · Business Wire Teva presented new data on its investigational olanzapine long-acting injectable and UZEDY A Core-tier name keeping a steady evidence cadence behind depot injectables defends a position that few competitors can replicate on manufacturing alone. Clinical evidence is part of the moat around long-acting injectable franchises. Sep 18 · NEWS · GlobeNewsWire Amneal won FDA approval for lanreotide injection and launched it immediately from in-house supply This is launch contribution in exactly the place the sector is trying to move toward: a complex injectable with internal production rather than commodity oral solids. Backward-integrated supply shortens the gap between an approval and revenue on the shelf. Sep 16 · NEWS · PRNewsWire Viatris announced Japanese approval of WAKIX (pitolisant) for narcolepsy and daytime sleepiness A new-market approval adds geographic diversification and earnings that do not sit in the eroding base portfolio. NeuraCap read: portfolio mix, not volume, is where the period's news was concentrated. Approvals outside the US widen the channel mix away from consolidated purchasing consortia. Sep 23 · NEWS · GlobeNewsWire Teva posted its Q3 2026 aide memoire to the investor section of its website A routine pre-quarter communication signals a company managing investor expectations on a set cadence rather than in reaction. Consistent investor communication is part of how Core-tier names hold their position. Sep 22 · NEWS · GlobeNewsWire A law firm said it is investigating claims on behalf of Dr. Reddy's Laboratories Limited investors Legal overhang is one of the factors that separates operating performance from equity outcomes in this sector, and acquirers examine proceedings early. Litigation exposure sits alongside the inspection record in how these assets are assessed. Sep 18 · NEWS · GlobeNewsWire Teva released post hoc data on olanzapine LAI (TEV-'749) from its pivotal programme Follow-on analysis keeps an investigational once-monthly injectable in front of prescribers while the programme advances. Pipeline visibility on complex dosage forms shapes how the set is positioned.
- 05M&A & STRATEGIC ACTIVITY
A Quiet Window for Transactions, with the Reference Record Unchanged
This page reports that no new sector transactions were announced in the period and restates the standing precedent record.
No material sector transactions were announced during this window, so the reference record carried into the period is the one carried out of it: a median of 11.7x EV/LTM EBITDA across 40 recorded deals. That multiple continues to sit above the 7.5x sector median on CY2027E EBITDA, a gap the public market moves this period did not close. For acquirers, that means underwriting still rests on the same comparable set until a new transaction resets it.
Everything on this page
M&A & STRATEGIC ACTIVITY A Quiet Window for Transactions, with the Reference Record Unchanged September 14–28, 2026 · precedent transactions: 40 recorded deals · median 11.7x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing transaction record still carries a median of 11.7x EV/EBITDA, against a 7.5x sector median on CY2027E EBITDA. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against 11.7x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
- 06WHAT IT MEANS
What the Two-Week Period Changes for Operators, Buyers and Advisers
This page translates the period's evidence into observations for operators, acquirers and advisers.
For owners and operators, launch cadence and dosage-form mix were the metrics that showed up this period, with eight of ten names rising on a median move of +8.8%. For acquirers, the precedent record stood still at 11.7x EV/EBITDA against a 7.5x sector median, so the same reference set applies until a new deal arrives. For advisers, the period's evidence argues for leading with complexity and the quality record — Amneal's lanreotide launch and Viatris' WAKIX approval are the concrete examples. These are observations drawn from the recorded evidence, not recommendations.
Everything on this page
WHAT IT MEANS What the Two-Week Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 7.5x 10 companies in the study 3 valuation tiers Standing thesis: Generic and Non-Prescription Drugs Is Priced in Three Tiers, and Complex Generics Hold Most of the Set FOR OWNERS & OPERATORS Launch Cadence and Dosage-Form Mix Were the Metrics That Showed Up Companies in the space traded higher, with 8 of 10 covered names rising and a median move of +8.8%. The window's news sat on new launch contribution, complex generics mix and internal supply. FOR ACQUIRERS Public Marks Moved While the Precedent Record Stood Still No new transactions landed in the window, so the reference set is the same one you carried in: a trailing median of 11.7x EV/EBITDA against a 7.5x sector median on CY2027E EBITDA. FOR ADVISORS Lead with Complexity and the Quality Record, Not the Base Business The period's evidence is specific: Amneal's approval and immediate launch of lanreotide injection, Viatris' Japanese approval of WAKIX, and Teva's continuing evidence programme behind long-acting injectables.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
This page explains what each figure in the update is sourced from and how driver attributions are calibrated.
Every figure on this page traces back to a filing, a published price record, or a linked article from the period, so nothing here is asserted without a record behind it. We use calibrated language throughout: a driver is stated only when a filing or headline supports it, and causation is never claimed where the evidence shows association. This is what lets the read in this update be relied on without re-checking every line.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Generic and Non-Prescription Drugs Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T174032Z_552_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com · prnewswire.com
Sources and methodology
This update covers Generic and Non-Prescription Drugs over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). No covered name fell below the floor in this window.
Window and company universe
This update covers Generic and Non-Prescription Drugs over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). No covered name fell below the floor in this window.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +19.0% (globenewswire.com)
- +14.6% (defenseworld.net)
- -1.4% (zacks.com)
- Teva presented new data on its investigational olanzapine long-acting (businesswire.com)
- Viatris announced Japanese approval of WAKIX (pitolisant) for narcolepsy (prnewswire.com)
- Teva posted its Q3 2026 aide memoire to the investor section of its (globenewswire.com)
- A law firm said it is investigating claims on behalf of Dr. Reddy's (globenewswire.com)
- Teva released post hoc data on olanzapine LAI (TEV-'749) from its pivotal (globenewswire.com)
- globenewswire.com (globenewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Generic and Non-Prescription Drugs Sector Outlook — September 2026
- M&A Update · 29 September 2026Genetic and Screening Services M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Genetic and Screening Services Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Data and Analytics M&A update, 14–28 September 2026
Want this analysis for a company in Generic and Non-Prescription Drugs?
Company valuation reports run the same method against a single business — public or private.
